Protagonist Therapeutics, Inc. Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

PTGX

Clasificación en acciones #2295
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Precio por acción
$134.37
Última sincronización: 2026-10-19
Capitalización bursátil
$8.70B
Cambio (1 día)
4.37%
Cambio (1 año)
75.15%
País
US
Comercio Protagonist Therapeutics, Inc. (PTGX)

Categoría

Healthcare
Historial de dividendos de Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. (símbolo bursátil: PTGX) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Protagonist Therapeutics, Inc. (PTGX) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL